MN-ST.-JUDE-MEDICAL
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that it will have new data featured during late-breaking clinical trial presentations at the upcoming 2016 Transcatheter Cardiovascular Therapeutics educational meeting in Washington, D.C., October 29 – November 2. Throughout the congress, the company will also feature its latest cardiovascular innovations, including PressureWire™ X guidewire, the latest generation of the pioneering PressureWire guidewire system; structural heart solutions and the CardioMEMS™ HF System.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161024005224/en/
Three late-breaking or first report investigation sessions and one oral abstract presentation will highlight data from St. Jude Medical advancements in vascular and structural heart technologies.
- A comparison of stent visualization technologies for use during percutaneous coronary intervention (PCI) – Data from the first randomized clinical trial to compare OCT-guided, IVUS-guided and angiography-guided PCI
The session: “ILUMIEN III (OPTIMIZE PCI): A Prospective, Randomized Trial of OCT-Guided vs. IVUS-Guided vs. Angio-Guided Stent Implantation in Patients with Coronary Artery Disease,” will be presented by Dr. Ziad A. Ali, associate director of translational medicine at the Center for Interventional Vascular Therapy at Columbia University Medical Center in New York at 9 a.m. on Sunday, October 30. This is the first late-breaking clinical trial presentation of TCT 2016.
- Final long term results from the RESPECT trial, comparing recurrent stroke in patients with the AMPLATZER™ PFO closure device to contemporary medical management
The session: “RESPECT: Final Long-Term Outcomes from a Prospective, Randomized Trial of PFO Closure in Patients with Cryptogenic Stroke,” will be presented by Dr. David Thaler, neurologist-in-chief at Tufts Medical Center and chairman of the Department of Neurology at Tufts University School of Medicine in Boston, at 12:15 p.m. on Tuesday, November 1.
Previous results observed a stroke reduction across the totality of analyses with rates ranging from 51-73 percent.
- Initial data from the largest, prospective evaluation of the AMPLATZER™ Amulet™ LAA occluder device, designed to seal the left atrial appendage to prevent stroke in patients with non-valvular atrial fibrillation
The session: “AMULET OBSERVATIONAL STUDY: Multicenter, Prospective, Registry Results with a Left Atrial Appendage Closure Device for Stroke Prevention in Patients with Atrial Fibrillation,” will be presented by Dr. David Hildick-Smith, cardiologist at Brighton & Sussex University Hospitals in the UK, at 9:40 a.m. on Wednesday, November 2.
Leading interventional cardiologists will also be on hand to demonstrate the OPTIS™ integrated system from 10-11 a.m. and from 2-3 p.m. each day during exhibit hours (Sunday, Oct. 30, Monday, October 31 and Tuesday, November 1).
Additionally, on Sunday, October 31, St. Jude Medical is sponsoring a TCT satellite symposium, "Interventional management of complex patients, cutting edge technologies for the advanced interventionalist.” For more information about this event, visit: http://www.crf.org/tct/agenda/satellite-programs .
About St. Jude Medical
St. Jude Medical is a leading global medical device manufacturer and is dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has five major areas of focus that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management, and cardiovascular. For more information, please visit sjm.com or follow us on Twitter @SJM_Media .
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the company, including potential clinical successes, reimbursement strategies, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the company’s control and the risk factors and other cautionary statements described in the company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 2, 2016. The company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024005224/en/
Contact:
St. Jude Medical, Inc.
J.C. Weigelt, 651-756-4347
Investor
Relations
jweigelt@sjm.com
or
Gina
O’Connell, 651-756-3380
Media Relations
Goconnell02@sjm.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology to Acquire Wolters Kluwer’s Finance, Risk & Regulatory Reporting Business Unit (FRR)21.7.2025 08:00:00 CEST | Press release
Expanding Regulatory Intelligence Platform and Global Reach Regnology, a leading software provider with a focus on regulatory reporting solutions, today announced it has entered into a definitive agreement to acquire Wolters Kluwer’s Finance, Risk & Regulatory Reporting (FRR) unit. The proposed acquisition represents a strategic step in Regnology’s ambition to deliver regulatory intelligence at scale—bringing together complementary capabilities across finance, risk, and regulatory reporting. It also expands Regnology’s presence in key markets and strengthens its ability to support financial institutions with granular data, jurisdiction-specific requirements, and cross-border compliance. Rob Mackay, CEO of Regnology, said: “FRR brings additional expertise and reach that will enhance our ability to serve clients globally. We look forward to supporting clients with a unified platform that helps them modernize their infrastructure, navigate Basel IV, and prepare for the future of regulator
EUMETSAT Takes Control of Europe’s First Geostationary Sounder Satellite21.7.2025 08:00:00 CEST | Press release
After more than two weeks of complex manoeuvring, precise positioning and meticulous checks, EUMETSAT assumed control of the Meteosat Third Generation Sounder 1 (MTG-S1) spacecraft on 18 July 2025, the latest addition to its fleet of geostationary meteorological satellites. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250720937880/en/ MTG-S1 in orbit Following MTG-S1’s successful launch on 1 July 2025, the satellite, which carries the Infrared Sounder (IRS) and the European Union’s Copernicus Sentinel-4 mission, has completed its launch and early operations phase (LEOP) and is now in orbit around 36,000km above the Equator at 3.4°W longitude. MTG-S1 will now begin months of intensive testing by experts at EUMETSAT with partners from the European Space Agency (ESA) and in industry to prepare for the delivery of vital data and products to specialists across EUMETSAT member states and beyond. Once fully commissioned, the sate
The Coca-Cola Company Names New Leader for Europe Operating Unit18.7.2025 21:00:00 CEST | Press release
The Coca-Cola Company today announced that Luisa Ortega will become president of the Europe operating unit effective Sept. 1, succeeding Nikos Koumettis, who will retire in 2026 after a 25-year career with the company. Koumettis will remain with the company through Feb. 28, 2026, as a senior advisor. He will also serve on the board of directors of Hindustan Coca-Cola Beverages Pvt. Ltd., a company-owned bottler in India. Ortega joined Coca-Cola in 2019 and currently serves as president of the Africa operating unit. In this role, she leads a complex business that operates across 54 markets. Koumettis has led the Europe operating unit since it was created in 2021. “Luisa has done an outstanding job leading our African business, where our system has continued to make major investments to serve growing markets on the continent,” said Henrique Braun, Executive Vice President and Chief Operating Officer of The Coca-Cola Company. “As head of Europe, she will bring great international experien
NFL Running Back Derrick Henry Joins Amazfit as Athlete Ambassador18.7.2025 15:00:00 CEST | Press release
Henry to utilize Amazfit products to optimize health, recovery and performance as he enters his 10th NFL season Amazfit, a leading global smart wearables brand owned by Zepp Health (NYSE: ZEPP), announced Baltimore Ravens running back Derrick Henry as the newest elite athlete to join its growing roster of ambassadors. Known for his rare combination of speed and strength, Henry will utilize Amazfit wearables to power every phase of his training, recovery and sleep as he prepares for his 10th NFL season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250718322498/en/ Derrick Henry is the newest elite athlete to join Amazfit's growing roster of ambassadors. As one of the most prolific running backs of his generation, Henry has amassed an impressive array of accolades during his career, including NFL Offensive Player of the Year, two rushing titles, and five Pro Bowl selections. With Amazfit as his official smart wearable partne
Qualcomm Announces Quarterly Cash Dividend18.7.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on September 25, 2025, to stockholders of record at the close of business on September 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom